CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

Data Compilation
#PharmaFlow

Pipeline Prospector Nov 2024: Trump’s HHS pick drags down jab makers’ stocks; Novartis, Merck, Roche ink billion-dollar deals

Stock Recap
#PipelineProspector

Torsemide

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

45 API Suppliers, 21 USDMF, 19 CEP/COS, 1 JDMF, 8 EU WC, 3 KDMF, 13 NDC API, 29 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

12 Intermediates Suppliers

12 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

215 FDF Dossiers, 48 FDA Orange Book, 122 Europe, 5 Canada, 14 South Africa, 26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 1 DKSH, 4 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 12 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 1 BioSpectra, 1 Clariant, 6 DFE Pharma, 6 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 25 Kerry, 12 Microlex e.U, 2 Novo Excipients, 4 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 15 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 10 Sigachi Industries, 2 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

69 Fillers, Diluents & Binders, 36 Direct Compression, 30 Disintegrants & Superdisintegrants, 20 Granulation, 18 Co-Processed Excipients, 17 Thickeners and Stabilizers, 13 Lubricants & Glidants, 9 Solubilizers, 8 Controlled & Modified Release, 8 Chewable & Orodispersible Aids, 6 Parenteral, 5 Coating Systems & Additives, 5 Taste Masking, 3 Film Formers & Plasticizers, 3 Topical, 3 Emulsifying Agents, 2 API Stability Enhancers, 2 Rheology Modifiers, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 5 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 103 Finished Drug Prices

MARKET PLACE

12 APIs, 12 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

2 US Patents, 5 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 5 USP, 14 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/11/2024	TAPI Technology & API Services	Israel	TEVA PHARMACEUTICAL INDUSTRIES LTD	15738	TORSEMIDE	2001-11-26	Active	II	N/A
28/11/2024	TAPI Technology & API Services	Israel	TEVA PHARMACEUTICAL INDUSTRIES LTD	15222	TORSEMIDE	2001-01-03	Inactive	II	N/A

Torsemide

Torsemide

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

45 API Suppliers

21 USDMF

19 CEP/COS

1 JDMF

8 EU WC

3 KDMF

13 NDC API

29 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

12 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

215 FDF Dossiers

48 FDA Orange Book

122 Europe

5 Canada

14 South Africa

26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

1 DKSH

4 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

12 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 Alcedo Pharmachem

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

14 BASF

1 BioSpectra

1 Clariant

6 DFE Pharma

6 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

25 Kerry

12 Microlex e.U

2 Novo Excipients

4 Pharmatrans-Sanaq

4 Pluviaendo

3 Prachin Chemical

15 Roquette

1 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

10 Sigachi Industries

2 Ulanqab Kema New Material

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

69 Fillers, Diluents & Binders

36 Direct Compression

30 Disintegrants & Superdisintegrants

20 Granulation

18 Co-Processed Excipients

17 Thickeners and Stabilizers

13 Lubricants & Glidants

9 Solubilizers

8 Controlled & Modified Release

8 Chewable & Orodispersible Aids

6 Parenteral

5 Coating Systems & Additives

5 Taste Masking

3 Film Formers & Plasticizers

3 Topical

3 Emulsifying Agents

2 API Stability Enhancers

TABLET;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons